• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pediatrics

ADHD stimulant treatment associated with changes in BMI trajectory

byBrandon ChildsandWilliam Raszka, MD
March 17, 2014
in Pediatrics, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD/CDC/ Debora Cartagena

1. Among adolescents, unmedicated childhood attention-deficit/hyperactivity disorder (ADHD) was associated with faster BMI growth after age 10 when compared to those undiagnosed with ADHD and without stimulant treatment.

2. ADHD stimulant treatment was associated with slower rates of BMI growth in childhood, faster growth in adolescence, and elevated BMI as an adolescent.  

Evidence Rating Level: 2 (Good)   

Study Rundown: Attention-deficit/hyperactivity disorder (ADHD) is a commonly diagnosed psychiatric disorder among pediatric patients that is often treated with stimulant medication.  Previous research has indicated a potential link between ADHD and growth deficits as well as obesity. In the current study, researchers sought to further investigate the potential association between ADHD diagnosis, stimulant-treated ADHD, and timing/duration of stimulant use with childhood BMI trajectories. Results indicated that a diagnosis of ADHD alone was associated with more rapid increases in BMI after the age of 10. Stimulant use, compared to other ADHD treatments, was linked to slower growth in childhood but accelerated growth and increased BMI in late adolescence. Earlier age of stimulant use and longer stimulant treatment duration were associated with greater effects on BMI. Despite this study’s large sample size, its homogenous white population limits generalizability to a racially diverse population. Taking into account this possible link, physicians should be mindful of the medications that they prescribe to patients with ADHD and also be prepared to initiate interventions if BMI approaches unhealthy ranges.

Click to read the study, published today in Pediatrics

Relevant Reading: Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder

RELATED REPORTS

Improved diet quality may be associated with increased longevity and better aging in Israeli adults

Overdoses in youth with benzodiazepine and stimulant prescriptions

Maternal substance use may increase risk of childhood Attention Deficit Hyperactivity Disorder

In-Depth [retrospective cohort study]:  A total of 163 820 (50% male, 91% white, mean age = 9 years)  files from pediatric patients ages 3-18 years old were examined from the Geisinger Health System, a primary healthcare system in central and northeastern Pennsylvania. Sociodemographics, vital signs, laboratory values, procedures, and medications of each patient were extracted from medical records. Linear regression models were used to evaluate childhood BMI trajectories with respect to ADHD diagnosis, stimulant use, age of first stimulant use, and duration of stimulant use. Children with an ADHD diagnosis and stimulant use grew slower in childhood but more rapidly in adolescence (p < 0.0001). Children with an ADHD diagnosis and without stimulant use displayed rapid BMI growth after 10 years of age (p < 0.0001) compared with controls (children without an ADHD diagnosis or stimulant use). Earlier age of stimulant use and longer duration stimulant use independently associated with significantly slower initial BMI growth in childhood and increased growth in adolescence when compared to controls.

More from this author: Current BMI standards may be predictive of metabolic syndrome, Increased cognitive activity post-concussion associated with prolonged symptom duration, Early adiposity rebound associated with worse metabolic markers, Dramatic rise of gun violence seen in PG-13 movies, Increased sleep linked to lower dietary intake in children  

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: ADHDBMIstimulants
Previous Post

2 Minute Medicine Rewind March 10 – 17, 2014

Next Post

HIV infection may increase rate of HCV-related hepatic decompensation

RelatedReports

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Improved diet quality may be associated with increased longevity and better aging in Israeli adults

June 28, 2022
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Overdoses in youth with benzodiazepine and stimulant prescriptions

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Maternal substance use may increase risk of childhood Attention Deficit Hyperactivity Disorder

March 15, 2022
Sleep duration inversely related to childhood type 2 diabetes risk makers
Wellness

Physical activity has a weight-independent effect on mortality

January 31, 2022
Next Post
New pathogenic dimorphic fungal species suggested in HIV-positive patients

HIV infection may increase rate of HCV-related hepatic decompensation

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

COPD associated with increased risk for nonamnestic-mild cognitive impairment

Influenza vaccine associated with lower risk of major cardiovascular events

Estimated three quarters of people with influenza are asymptomatic [Flu Watch study]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
  • Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.